期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 384, 期 6, 页码 581-583出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMc2031717
关键词
-
Two patients developed severe refractory autoimmune colitis after cancer treatment with immune checkpoint inhibitors, but responded well to a course of subcutaneously administered ustekinumab, an antibody that blocks interleukin-12/23 signaling.
Two patients in whom severe refractory autoimmune colitis developed after cancer treatment with immune checkpoint inhibitors had a response to a course of subcutaneously administered ustekinumab, an antibody that blocks interleukin-12/23 signaling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据